VR Logo

Molecular Partners AG (MOLN) download report


Healthcare | Biotechnology & Pharma Research

Molecular Partners AG (MOLN) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins.

IPO Date: 16-Jun-2021

Co-Founder, CEO, Member of Management Board & Director: Dr. Patrick Amstutz Ph.D.

Co-Founder, COO & Member of Management Board: Dr. Michael Tobias Stumpp Ph.D.

Listing: NASDAQ: MOLN

Country: Switzerland

Headquarters: Schlieren,

Website: https://www.molecularpartners.com

Key Facts

Market cap: $286.03 Mln

Revenue (TTM): CHF180.90 Mln

Earnings (TTM): CHF105.90 Mln

Cash: CHF296.25 Mln

Total Debt: CHF5.74 Mln

Insider's Holding: 0.00%

Liquidity: Low

52 Week range: $5.92 - 32.04

Shares outstanding: 32,325,700

9 Years Aggregate:

  • CFO: CHF-237.45 Mln
  • EBITDA: CHF-224.39 Mln
  • Net Profit: CHF-239.21 Mln

Stock Performance

Time Period Molecular Partners AG (MOLN) S&P BSE Sensex* S&P Small-Cap 600*
YTD-63.71-8.99-19.22
1 month-9.73-3.40-9.34
3 months-66.55-8.50-14.58
1 Year-66.870.89-17.64
3 Years-21.8110.415.91
5 Years-25.8011.435.64
10 Years--11.7710.10
As on 29-Jun-2022 *As on 30-Jun-2022
Year Molecular Partners AG (MOLN) S&P Small-Cap 600 S&P BSE Sensex
2021-7.5525.2721.99
202018.449.5715.75
2019-8.0420.8614.38
2018-27.53-9.705.87
20176.0511.7327.91
2016-29.1424.741.95
201539.17-3.36-5.03